Imaging Scans Studied in Cervical, Endometrial and Ovarian Cancer
Studies PET scans to see if imaging predicts outcomes in gynecological cancers.
Plain-language title generated from the registry record
Registry title: Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)
Key facts
- Where
- Umeå, SwedenSee the site
Where in Sweden
- Centre for Gynecology and Obstetrics, Umea University HospitalUmeå, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Västerbotten
- Trial code
- NCT05855941
- Record updated
- 16 December 2024
- Original description
The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are:Read full original descriptionShow less
Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer (PRODIGYN)
The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are:
* Does advanced medical imaging predict survival? * Can advanced medical imaging improve radiotherapy target planning? * Are advanced medical imaging results associated with risk markers found in tumor tissue?
Participants will
* Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months. * Be subject to clinical follow-up for five years.
Inclusion: Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer; Known clinical FIGO stage; >18 years old; No other known current or previous malignancy within the last 10 years.
Exclusion: Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or "cancer abdominis"; Imaging findings suggestive of other primary malignancy; MRI incompatible devices or patient unable to undergo MRI.